AltTox.org

Non-animal Methods for Toxicity Testing

In the Spotlight
Meetings & Events
Get Involved

References: Bailey


Last Updated: September 3, 2008
Print |
Email
  1. Brent, R.L. (1995). The application of the principles of toxicology and teratology in evaluating the risks of new drugs for treatment of drug addiction in women of reproductive age. NIDA Res. Monogr. 149, 130-184.
  2. National Research Council; Committee on Toxicity and Assessment of Environmental Agents. (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academies Press; 146.
  3. Bailey, J., Knight, A. & Balcombe, J. (2005). The Future of Teratology Research is In Vitro. Biogenic Amines - Stress and Neuroprotection. 19, 97-145.
  4. Klasco, R.K. & Heitland, G. REPRORISK® System.
  5. Schardein, J.L. (1993). Chemically Induced Birth Defects. New York: Dekker; xiv. 902 p.
  6. United States Food and Drug Administration. (1980). Caffeine: Deletion of GRAS Status, Proposed Declaration That No Prior Sanction Exists, and Use on an Intern Basis Pending Additional Study. Federal Register. 45, 69817.
  7. European Parliament Memo. (2006). Q & A on the New Chemicals Policy, REACH. MEMO/06/488.
  8. Kotwani, A., Mehta, V.L. & Iyengar, B. (1995). Aspirin By Virtue of Its Acidic Property May Act as Teratogen in Early Chick Embryo. Indian J. Physiol. Pharmacol. 39, 131-134.
  9. Polifka, J.E. & Friedman, J.M. (1999). Clinical Teratology: Identifying Teratogenic Risks in Humans. Clin. Genet. 56, 409-420.
  10. Genschow, E., Scholz, G., Brown, N., Piersma, A., et al. (2000). Development of Prediction Models for Three In Vitro Embryotoxicity Tests in an ECVAM Validation Study. In Vitro Mol. Toxicol. 13, 51-66.
  11. Genschow, E., Scholz, G., Brown, N.A., Piersma, A.H., et al. (1999). [Development of Prediction Models for Three In Vitro Embryotoxicity Tests Which are Evaluated in an ECVAM Validation Study]. ALTEX. 16, 73-83.
  12. Scholz, G., Pohl, I., Genschow, E., Klemm, M., et al. (1999). Embryotoxicity Screening Using Embryonic Stem Cells In Vitro: Correlation to In Vivo Teratogenicity. Cells Tissues Organs. 165, 203-211.
  13. Scholz, G., Genschow, E., Pohl, I., Bremer, S., et al. (1999). Prevalidation of the Embryonic Stem Cell Test (EST)-A New In Vitro Embryotoxicity Test. Toxicol. In Vitro. 13, 675-681.
  14. Spielmann, H., Pohl, I., Döring, B., Liebsch, M., et al. (1997). The Embryonic Stem Cell Test (EST), an In Vitro Embryotoxicity Test Using Two Permanent Mouse Cell Lines: 3T3 Fibroblasts and Embryonic Stem Cells. In Vitro Toxicol. 10, 119-127.
  15. Adler, S., Pellizzer, C., Hareng, L., Hartung, T., et al. (2008). First Steps in Establishing a Developmental Toxicity Test Method Based on Human Embryonic Stem Cells. Toxicol. In Vitro. 22, 200-211.
  16. Seiler, A., Buesen, R., Hayess, K., Schlechter, K., et al. (2006). Current status of the embryonic stem cell test: the use of recent advances in the field of stem cell technology and gene expression analysis. ALTEX. 23, Suppl. 393-399.
  17. Heikkila, A.M., Erkkola, R.U. & Nummi, S.E. (1994). Use of Medication During Pregnancy--A Prospective Cohort Study on Use and Policy of Prescribing. Ann. Chir. Gynaecol. Suppl. 208, 80-83.
  18. McElhatton, P. (2002). Teratogenic Drugs – Part 1. Adv. Drug React. Bull. 213, 815-818.
  19. Peters, P. (1998). General Commentary to Drug Therapy and Drug Risks in Pregnancy. In: CH S, editor. Drugs During Pregnancy and Lactation. Amsterdam: Elsevier; pp1-13.